Bayforest Capital LTD Biocryst Pharmaceuticals Inc Transaction History
Bayforest Capital LTD
- $229 Billion
- Q2 2025
A detailed history of Bayforest Capital LTD transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Bayforest Capital LTD holds 93,722 shares of BCRX stock, worth $601,695. This represents 0.37% of its overall portfolio holdings.
Number of Shares
93,722Holding current value
$601,695% of portfolio
0.37%Shares
1 transactions
Others Institutions Holding BCRX
# of Institutions
315Shares Held
201MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$132 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$128 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$54.6 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$54.3 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$36.7 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.19B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...